On April 17, 2026 OncoNano Medicine, Inc. ("OncoNano"), a clinical-stage biotechnology company developing precision therapies using its proprietary nanotechnology platform, reported it will present new preclinical data at the AACR (Free AACR Whitepaper) Annual Meeting 2026. The presentations highlight the breadth of its ON-BOARD platform and its ability to enable effective, tumor-targeted delivery of therapeutic payloads through clinically validated ultra pH-sensitive micelle technology designed to activate within the tumor microenvironment.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our ON-BOARD platform is designed to overcome key limitations of existing delivery approaches, including reliance on tumor-associated antigens and off-tumor toxicities," said Kartik Krishnan, MD, PhD, Chief Executive Officer of OncoNano. "These data demonstrate the versatility of our platform across multiple payloads and reinforce its potential to deliver profound efficacy with an improved therapeutic index."

Poster Presentation Details

A Polymer-Drug Conjugate Platform for Tumor Specific Drug Delivery: Advancement of a Clinically Validated Ultra pH-Sensitive Micelle Technology
Presenter: Qingtai Su, PhD, Senior Scientist
Session Date/Time: April 20, 2026 | 2:00–5:00 PM PT
Location: Poster Section 14 | Board #17 | Poster #3026

This presentation highlights the breadth and tunability of the ON-BOARD platform, demonstrating tumor-specific delivery of multiple cytotoxic compounds through targeting the acidic tumor microenvironment. Preclinical data show strong in vitro and in vivo anti-tumor activity across a range of payload-linker combinations, including superior tumor growth inhibition and robust responses compared to standard-of-care agents. Findings further illustrate the ability to modulate payload release through linker design, supporting a differentiated, antigen-independent approach to drug delivery.

ONM-421, a pH-Responsive Polymer-Drug Conjugate Nanoparticle, Delivers MMAE to Solid Tumors and Shows Antigen-Independent Antitumor Efficacy in Mice
Presenter: Jason Miller, PhD, Associate Director
Session Date/Time: April 20, 2026 | 2:00–5:00 PM PT
Location: Poster Section 14 | Board #12 | Poster #3021

Building on the platform’s versatility, this presentation features ONM-421 as a lead example of ON-BOARD–enabled delivery. Preclinical findings demonstrate potent, antigen-independent anti-tumor efficacy across multiple xenograft models, including strong tumor growth inhibition and survival benefit. ONM-421 showed broader activity compared to an MMAE-based antibody-drug conjugate, including efficacy in tumors with low target expression where the ADC was less active. In these models, ONM-421 also demonstrated improved tolerability relative to a standard chemotherapy when given at an efficacious dose. These data highlight enhanced payload stability and protection during circulation, reinforcing the platform’s ability to enable targeted tumor delivery while reducing off-target toxicity.

(Press release, OncoNano Medicine, APR 17, 2026, View Source [SID1234664499])

On April 17, 2026 NEOK Bio, Inc., an oncology therapeutics company focused on the development of novel antibody drug conjugates (ADCs) for improving outcomes for cancer patients, reported that two poster presentations highlighting its ADC pipeline will be delivered at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026 taking place April 17-22, 2026, in San Diego, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The AACR (Free AACR Whitepaper) 2026 presentations will showcase NEOK’s emerging pipeline of next-generation ADCs engineered to target proteins broadly expressed across tumor types with high unmet need. The company will present new findings for its two lead bispecific candidates: NEOK001, a first-in-class "2+2" bispecific ADC designed to target B7-H3 and ROR1-expressing tumors, and NEOK002, a "1+1" bispecific ADC targeting EGFR (epidermal growth factor receptor) and MUC1 (Mucin 1)-expressing solid tumors. Both therapies utilize Synaffix’s proprietary, validated linker-payload technology with a DAR 4 Topoisomerase-1 (Topo-1) inhibitor, exatecan (SYNtecan E ).

Both programs have received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA), and NEOK plans to initiate Phase 1 clinical trials in 2Q 2026, with initial clinical data readouts anticipated in 2027. Both of NEOK’s bispecific ADC candidates will enter the clinic on a foundation of promising preclinical studies, where they have demonstrated superior in vivo efficacy in solid tumors compared to traditional monovalent ADCs.

Preclinical data will be shared in two separate poster presentations on April 20 during the session titled "Antibody Drug Conjugates and Linker Engineering 2" at AACR (Free AACR Whitepaper) 2026. Highlights of the presentations include:

Poster 1724: NEOK001: A first-in-class B7-H3xROR1 bispecific ADC demonstrated enhanced efficacy and promising tolerability

Potent dual‑target cytotoxicity and strong bystander killing, supporting activity in heterogeneous solid tumors
Broad efficacy across 38 PDX models, achieving 84% tumor growth inhibition and 53% deep tumor regression across nine major cancer types
Outperformed clinical benchmark ADCs, including I‑Dxd and zilovertamab vedotin, and successfully regressed I‑Dxd-treated regrowing tumors
Observed favorable safety profile in GLP toxicology studies (HNSTD: 60 mg/kg) with stable DAR and predictable pharmacokinetics
Poster 1726: NEOK002: Designing an EGFRxMUC1 Bispecific TOP1i ADC with Promising Anti-Tumor Activity and Enhanced Therapeutic Window

Dual-targeting design enhances binding and internalization in dual-positive tumor cells while reducing off‑tumor EGFR engagement
Robust antitumor activity across 36 PDX models, achieving tumor regressions in 78%, including KRAS‑mutant and heavily pretreated tumors
Favorable safety profile with minimal impact on keratinocyte proliferation and reduced inhibition of EGFR signaling versus cetuximab-based ADCs
Strong combination potential sotorasib, enabling extended tumor regression for 58 days in KRAS G12C-mutant models
"These preclinical findings underscore the potential of our next-generation ADC pipeline to overcome the limitations of conventional monovalent designs," said Mayank Gandhi, MD, CEO of NEOK Bio. "As we prepare to accelerate both candidates into clinical development, we look forward to sharing their differentiated mechanisms and compelling pre-clinical activity at ACCR 2026."

(Press release, Neok Bio, APR 17, 2026, View Source [SID1234664498])

On April 17, 2026 SingleCell Biotechnology, a biotechnology company developing technologies to measure tumor cell behavior at single-cell resolution, reported the presentation of new data at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026 demonstrating an integrated, high-throughput assay capable of measuring clonal tumor cell growth across thousands of individual microenvironments while preserving the full distribution of proliferative behaviors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data show the platform can consistently measure differences in how individual tumor cells grow across multiple glioblastoma models. Importantly, it captures cell states that are often missed by traditional assays. It also enables tracking of single cells over time and recovery of specific cell populations for further analysis, allowing researchers to connect how cells behave with their underlying biology.

Tumor heterogeneity remains a major challenge in oncology drug development. Traditional preclinical approaches often rely on average responses across large groups of cells, which can miss the smaller populations that drive treatment resistance and disease progression. As a result, it remains difficult to identify and study the cells most responsible for relapse.

Presentation Details:
Poster Title: An Integrated High-throughput Assay for Proliferative Phenotypic and Omics
Presenter: Shiska Raut, Machine Learning Engineer
Poster ID: LB029
Session Date/Time: Sunday, April 19, 2026, 2:00 PM – 5:00 PM
Location: Poster Section 51, Board #9, San Diego Convention Center, San Diego, CA

(Press release, SingleCell Biotechnology, APR 17, 2026, View Source [SID1234664497])

On April 17, 2026 Orum Therapeutics ("Orum" or the "Company") (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), reported the presentation of new preclinical data for ORM-1153, a CD123-targeting DAC designed to selectively deliver a proprietary GSPT1-degrading payload, in development for the treatment of AML and other CD123-positive hematological malignancies. The data were presented in two posters at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These data show strong preclinical activity and the potential for a differentiated safety and tolerability profile, supporting the advancement of ORM-1153 as a next-generation CD123-targeting degrader-antibody conjugate for acute myeloid leukemia," said Chad May, Ph.D., Chief Scientific Officer of Orum. "Our approach combines a proprietary CD123-antibody and novel GSPT1-targeted protein degrader with the goal of achieving greater selectivity than conventional cytotoxic antibody-drug conjugates. We believe this strategy can enable more effective and better-tolerated therapies for patients with AML."

The first poster (Abstract Number: 1824) highlights how ORM-1153 was engineered with a proprietary CD123-antibody designed for enhanced internalization and reduced Fc-gamma receptor interactions, together with a linker optimized for plasma stability, an approach intended to improve delivery, reduce off-target and immune cell engagement, and support favorable pharmacologic properties. Consistent with that design, ORM-1153 showed strong preclinical anti-leukemia activity at low doses, along with prolonged accumulation in tumors, undetectable systemic free payload, and favorable repeat-dose non-human primate findings supporting a manageable safety and tolerability profile.

Data from the second poster (Abstract Number: 1710) extend Orum’s previously presented findings by showing activity across primary AML patient samples and in models with relevant tumor mutations, including TP53. Taken together, the findings support the potential for broad activity in AML, including in patients with TP53 mutations.

"These AACR (Free AACR Whitepaper) data are particularly encouraging in the context of AML, where many patients, especially those with TP53 mutations, continue to have limited treatment options and poor outcomes," said Olaf Christensen, M.D., Chief Medical Officer of Orum. "The activity we are seeing across primary patient samples and TP53-relevant models, together with a consistent pharmacologic and tolerability profile, supports the continued advancement of ORM-1153 toward clinical development."

Both posters are available on Orum’s website and will be presented at AACR (Free AACR Whitepaper) on Monday, April 20, from 9 am to 12 pm PDT.

About ORM-1153

ORM-1153 is a CD123-targeting degrader-antibody conjugate developed using Orum’s Dual-Precision TPD² approach. The molecule is built from two proprietary elements, a GSPT1-degrading payload and an anti-CD123 antibody engineered for high internalization efficiency, conjugated with a cleavable β-glucuronide linker. By combining tumor-selective antibody delivery with targeted protein degradation, ORM-1153 is designed to induce cancer cell death through degradation of GSPT1, a protein implicated in cell survival, including in TP53-mutant AML, while minimizing effects on normal tissues.

About Orum’s TPD² Approach

Orum’s unique Dual-Precision Targeted Protein Degradation (TPD²) approach builds novel targeted protein degraders combined with the precise cell delivery mechanisms of antibodies to generate innovative, first-in-class, cell-selective TPDs for the treatment of cancer and other serious diseases. Orum has developed new targeted protein degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, the payloads are designed to be delivered specifically to target cells and precisely degrade the intracellular target protein of interest.

(Press release, Orum Therapeutics, APR 17, 2026, View Source [SID1234664496])

On April 17, 2026 Onchilles Pharma, a private biotech company advancing therapeutics targeting the ELANE pathway, reported new preclinical data from its NEU-002 program presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026. The poster highlights the translational development of NEU-002, an engineered therapeutic elastase program intended for systemic administration, and demonstrates anti-tumor activity following both intravenous (IV) and intraperitoneal (IP) delivery in preclinical solid tumor models.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"NEU-002 is designed to bring the ELANE pathway to more solid tumor indications that are not well served by local delivery," said Court R. Turner, J.D., Co-Founder and Chief Executive Officer of Onchilles Pharma. "The preclinical data presented at AACR (Free AACR Whitepaper) show anti-tumor activity after both IV and IP administration and move us closer to a systemic approach intended to kill tumors while preserving the immune response needed for durable control."

The data presented at AACR (Free AACR Whitepaper) show that candidates from the systemically delivered NEU-002 program achieved tumor biodistribution and anti-tumor activity in preclinical CT26 colon cancer models following both IV and IP administration. In a CT26 flank model, IV-delivery of a NEU-002 candidate drove complete tumor clearance in all treated animals and durable protection across multiple tumor rechallenges, consistent with long-term immune memory. In a separate CT26 visceral model, IP-delivery of a NEU-002 candidate reduced ascites and total tumor burden, supporting the potential of these NEU-002 candidates in settings relevant to disseminated abdominal disease.

NEU-002 was developed to extend the ELANE pathway beyond tumor-directed delivery through engineering intended to protect elastase activity against circulating serine protease inhibitors. Together, these findings support continued advancement of the NEU-002 program as a systemic approach for solid tumors, with two lead candidates moving forward for additional evaluation, including into non-human primate pharmacokinetic studies, to inform final development candidate selection.

About Onchilles Therapeutic Programs Targeting the ELANE Pathway

At the core of this approach is the ELANE pathway, a unique cancer-selective killing mechanism that leverages a vulnerability shared by many cancer cell types: elevated histone H1 levels. Our pipeline is led by N17350, our first-in-class, clinical-stage program, followed by NEU-002, the second program that extends this approach with systemic delivery. By targeting the ELANE pathway and inducing immunogenic cancer cell death, N17350 and NEU-002 are designed to rapidly eliminate tumors while mobilizing an adaptive immune response, offering the potential for sustained anti-tumor immunity. N17350 and NEU-002 offer a unique approach to treating cancer regardless of their genetic makeup, anatomical origin, or immune status, positioning them as potential gamechangers in cancer therapy.

(Press release, Onchilles Pharma, APR 17, 2026, View Source [SID1234664495])